Changes in guidelines for monitoring the metabolic syndrome have reduced cardiovascular risk in kidney transplant recipients and improved overall stability of kidney function. Researchers at the Nephrology and Hypertension Services, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, reported that controlling diabetes mellitus (DM) was challenging for the transplant recipients, but the new guidelines had an impact on clinical practice, which transformed to better control of the metabolic syndrome.
The study examined whether the new guidelines for treating metabolic syndrome had an impact on the management of post-transplantation patients and the following treatment outcomes.
‘Guidelines introduced by 'Kidney Disease - Improving Global Outcomes' had an impact on clinical practice, which transformed to better control of the metabolic syndrome. The guidelines help improve the overall stability of kidney function in transplant recipients reducing cardiovascular risk.’
AdvertisementMetabolic syndrome is a group of risk factors that occur together, increasing your risk of heart disease, stroke, and diabetes. These factors include hypertension, high blood sugar level, excess body fat around the waist and abnormal cholesterol levels. However, experiencing one of these conditions doesn't indicate that one has metabolic syndrome. Any of these conditions increases your risk of cardiovascular disease, and the risk is even greater if more than one of these medical conditions appear in combination.
Cardiovascular disease is a leading cause of death in kidney transplant recipients. Metabolic syndrome raises the risk for cardiovascular events and decreases graft survival. Recently, new guidelines for management of the metabolic syndrome, primarily hypertension, DM, and hypercholesterolemia - an excess of cholesterol in the bloodstream - have been introduced in an attempt to decrease cardiovascular risks among kidney transplant recipients.
Earlier, formal guidelines for special populations such as kidney transplant recipients were not as common as they have become in the last two decades. Instead, there were common practices as recommended treatment targets. 'Kidney Disease - Improving Global Outcomes' (KDIGO), developed in 2003, has suggested guidelines for management of patients with kidney diseases. The 2009 KDIGO guidelines offer recommendations for the supervision of kidney transplant recipients, including screening and treatment goals.
In order to study the effectiveness of these guidelines, the researchers obtained data from kidney transplant clinic files from two follow-up periods - between 1994 and 1997 and between 2008 and 2011. They compared demographic data in these two follow-up periods and the treatments including monitoring and screening frequency for cardiovascular risk, immune suppression regimen, treatment for high blood pressure, diabetes and hyperlipidemia.
Results showed that patient's monitoring and screening during the second follow-up period were less frequent but more targeted. This reflects changes in clinic routines. Blood pressure and hypercholesterolemia were better controlled in the second follow-up period. In the second group, high fasting glucose levels were more prevalent, although more patients received treatment for diabetes mellitus. Most significantly, fewer patients suffered from deterioration of kidney functions during the second follow-up period.
In conclusion, majority of the patients meet the treatment goals as pointed out by KDIGO, even though there are still a group of patients who needs further efforts to attain better clinical outcomes, especially regarding diabetes control. The researchers said that the significant improvement we saw in kidney function stability over time was most gratifying. Overall, the noted changes in the management of kidney transplant patients in the last decade, including better control of cholesterol levels and blood pressure are associated with improved graft function.
The study was published in the Journal, Diabetology & Metabolic Syndrome.
Reference:Inbal Houri, Keren Tzukert, Irit Mor-Yosef Levi, Michal Aharon, Aharon Bloch, Olga Gotsman, Rebecca Backenroth, Ronen Levi, Iddo Ben Dov, Dvora Rubinger and Michal Dranitzki Elhalel doi:10.1186/s13098-015-0083-7
You May Also Like